Home Cart Sign in  
Chemical Structure| 97-39-2 Chemical Structure| 97-39-2

Structure of Ditolylguanidine
CAS No.: 97-39-2

Chemical Structure| 97-39-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ditolylguanidine (1,3-Di-o-tolylguanidine) is an agonist of sigma receptor (σ1/σ2 receptor)[1].

Synonyms: 1,3-Di-o-tolylguanidine; DTG; NSC 473

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ditolylguanidine

CAS No. :97-39-2
Formula : C15H17N3
M.W : 239.32
SMILES Code : N=C(NC1=CC=CC=C1C)NC2=CC=CC=C2C
Synonyms :
1,3-Di-o-tolylguanidine; DTG; NSC 473
MDL No. :MFCD00008513
InChI Key :OPNUROKCUBTKLF-UHFFFAOYSA-N
Pubchem ID :7333

Safety of Ditolylguanidine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Ditolylguanidine

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
rat hippocampal slices 100 nM inhibited NMDA-evoked [3H]NE release Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3774-8
CA3 dorsal hippocampus pyramidal neurones 1 mM 15 to 20 minutes To evaluate the effect of DTG on NMDA-induced neuronal activation; in control animals, DTG significantly enhanced the NMDA response, but in PTX-pretreated animals, DTG induced a slight but significant reduction of NMDA-induced neuronal activation. Br J Pharmacol. 1994 Jun;112(2):709-15
rat hippocampal slices >100 nM 40 minutes DTG at concentrations greater than 100 nM inhibited NMDA-evoked [3H]-NA release, with maximal inhibition of 86% at 3 μM. Br J Pharmacol. 1996 Sep;119(1):65-72
mouse hippocampal neurons 50-300 μM 3 seconds DTG attenuated NMDA-evoked currents with an IC50 of 37±5 μM, showing minimal effects on kainate- and AMPA-evoked currents. Br J Pharmacol. 1993 Aug;109(4):1196-205
rat hippocampal neurons 10-100 μM 25 seconds DTG produced a concentration-dependent depression of NMDA-evoked rises in intracellular free calcium ([Ca2+]i), with lesser effects on kainate- and AMPA-evoked responses. Br J Pharmacol. 1993 Aug;109(4):1196-205
rat brain membranes 3.4 nM 90 minutes Investigate the binding sites of DTG in rat brain membranes, results showed DTG interacts with one binding site. Br J Pharmacol. 1992 Nov;107(3):726-31
guinea-pig brain membranes 3.4 nM 90 minutes Investigate the binding sites of DTG in guinea-pig brain membranes, results showed DTG interacts with at least two binding sites. Br J Pharmacol. 1992 Nov;107(3):726-31
rat hippocampal CA1 pyramidal neurons 15 μM 60 minutes Investigation of Ditolylguanidine's inhibitory effects on Mg2+-free induced epileptiform activity, showing reversible inhibition of evoked epileptiform field potentials with an IC50 of 15 μM. Br J Pharmacol. 1998 Jul;124(5):917-29

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats Rat nucleus accumbens shell microdialysis model Intravenous injection 1.0–5.6 mg/kg Single administration, observation time up to 45 minutes To evaluate the effects of DTG on dopamine levels in the nucleus accumbens shell, results showed that DTG dose-dependently increased dopamine levels, with the highest dose (5.6 mg/kg) peaking at 10 minutes post-administration, reaching approximately 150% of baseline levels. Biol Psychiatry. 2011 Feb 1;69(3):208-17
Sprague-Dawley rats PTX-pretreated rat model Intravenous injection 1 μg/kg Single injection To assess the modulatory effect of DTG on the NMDA response; in PTX-treated rats, DTG neither enhanced nor reduced the NMDA-induced neuronal activation. Br J Pharmacol. 1994 Jun;112(2):709-15
Mice Amnesia models induced by CO exposure or trimethyltin intoxication Subcutaneous injection 0.1 mg/kg Single administration, 30 minutes before testing DTG significantly reversed the spontaneous alternation deficits observed in mice after CO exposure or trimethyltin intoxication. Br J Pharmacol. 1999 May;127(2):335-42
Sprague-Dawley rats Rat dorsal hippocampus CA3 pyramidal neuron model Subcutaneous 100–1000 mg/kg/day 21-day treatment, 48-hour washout Long-term low-dose DTG (100 mg/kg/day) enhances NMDA responses, while high doses (1000 mg/kg/day) suppress this potentiation. Br J Pharmacol. 1997 Apr;120(7):1351-9

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03564613 HIV Infections RECRUITING 2024-10-30 GSK Investigational Site, Barc... More >>elona, 08041, Spain Less <<
NCT02259127 HIV Infection PHASE2|PHASE3 UNKNOWN 2025-05-23 Universitata Frankfurt, Frankf... More >>urt, Germany|UkE Eppendorf Hamburg, Hamburg, Germany|Centro Materno-Infantil de Norte, Porto, Portugal|King Edward VIII Hospital, Durban, South Africa|Africa Health Research Institute (AHRI), Hlabisa, South Africa|PHRU Klerksdorp, Klerksdorp, South Africa|Kid-Cru, Parow, South Africa|PHRU, Soweto, South Africa|Hospital San Joan de Defu, Barcelona, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital La Paz, Madrid, Spain|Nakornping Hospital, Chiang Mai, Thailand|Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand|Khon Kaen Hospital, Khon Kaen, Thailand|Mahasarakam Hospital, Maha Sarakham, Thailand|Prapokklao Hospital, Mueang Chanthaburi District, Thailand|Phayao Hospital, Phayao, Thailand|Baylor, Kampala, Uganda|JCRC, Kampala, Uganda|MUJHU, Kampala, Uganda|JCRC, Mbarara, Uganda|Birmingham Heartlands Hospital, Birmingham, United Kingdom|Leeds General Infirmary, Leeds, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Great Ormand Street Hospital, London, United Kingdom|Kings College Hospital, London, United Kingdom|St Mary's Hospital, London, United Kingdom|UZCRC, Harare, Zimbabwe Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.18mL

0.84mL

0.42mL

20.89mL

4.18mL

2.09mL

41.79mL

8.36mL

4.18mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories